Pharma BD Deal Intelligence

Boehringer Ingelheim International GmbH / Variant Bio

2026 · Licensing/Option · $250M · Pending

Variant Bio expanded its multi-year research collaboration and license agreement with Boehringer Ingelheim from kidney disease into cardiovascular disease. The expansion applies Variant Bio's AI-powered Inference platform, which runs end-to-end genomic analysis over proprietary genomic, deep-phenotyping and multi-omic data from diverse global populations, to discover and validate novel cardiovascular targets. Boehringer Ingelheim added potential payments exceeding USD 250 million, comprising an upfront payment, platform access payments and milestones. This is an expansion of the companies' existing kidney disease collaboration rather than a new standalone agreement.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Boehringer Ingelheim International GmbH deals